TRHC:NSD-Tabula Rasa HealthCare Inc.

EQUITY | Application Software | NASDAQ Global Market

Last Closing Price

USD 64.76

Change

-0.47 (-0.72)%

Market Cap

USD 1.33B

Volume

0.15M

Average Target Price

USD 81.63 (26.05%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Tabula Rasa HealthCare Inc provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-11-13 )

Largest Industry Peers for Application Software

Symbol Name Price(Change) Market Cap
MSFT Microsoft Corporation

+0.07 (+0.07%)

USD 820.89B
ADBE Adobe Inc.

+2.07 (+0.87%)

USD 116.54B
INTU Intuit Inc.

-0.03 (-0.01%)

USD 55.06B
CTSH Cognizant Technology Solutions..

+0.06 (+0.09%)

USD 40.31B
ATVI Activision Blizzard Inc

-1.34 (-2.49%)

USD 40.10B
WDAY Workday Inc.

+1.96 (+1.47%)

USD 29.31B
ADSK Autodesk Inc.

+0.81 (+0.62%)

USD 28.62B
EA Electronic Arts Inc.

-0.27 (-0.31%)

USD 26.40B
CERN Cerner Corporation

-0.35 (-0.62%)

USD 18.59B
CA CA Inc.

N/A

USD 18.58B

ETFs Containing TRHC

DWMC AdvisorShares Dorsey Wrig.. 1.29 % 0.00 %

-0.28 (-1.30%)

USD 2.66M
IWC iShares Microcap 0.34 % 0.60 %

-0.44 (-0.47%)

USD 0.94B

Market Performance

  Market Performance vs.
Industry/Classification (Application Software)
Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 130.87% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 130.87% 97% A+ 98% A+
Trailing 12 Months  
Capital Gain 122.70% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 122.70% 95% A 97% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 108.37% 98% A+ 98% A+
Dividend Return 108.37% 98% A+ 98% A+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 118.51% 6% F 5% F
Risk Adjusted Return 91.44% 79% C+ 81% B-
Market Capitalization 0.20B 57% F 74% C

Key Financial Ratios

  Ratio vs. Industry/Classification
(Application Software)
Ratio vs. Market
(NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -46.93 83% B 93% A
Price/Book Ratio 12.38 19% F 7% F
Price / Cash Flow Ratio 21.30 12% F 3% F
Price/Free Cash Flow Ratio 161.90 5% F 2% F
Management Effectiveness  
Return on Equity -29.63% 26% F 26% F
Return on Invested Capital -44.06% 14% F 22% F
Return on Assets -15.44% 22% F 28% F
Debt to Equity Ratio 16.25% 68% D+ 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

TRHC:NSD-Tabula Rasa HealthCare Inc.

EQUITY | Application Software | NASDAQ Global Market

Last Closing Price

USD 64.76

Change

-0.47 (-0.72)%

Market Cap

USD 1.33B

Volume

0.15M

Average Target Price

USD 81.63 (26.05%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-11-13